A patient at high thromboembolic risk had intracranial hemorrhage as an adverse effect of treatment with vitamin K antagonists. When can anticoagulation be restarted in this patient? What anticoagulants are recommended? Can low-dose low-molecular-weight heparins be started shortly after the hemorrhage?
In your opinion, are there any new trial results, drugs, or procedures in the field of thromboembolic disease that are worth particular attention?
Paget-Schroetter syndrome and subclavian vein thrombosis are very rarely discussed. Could you comment on these diseases and the risk of pulmonary embolism? Is this a risk for deep venous thrombosis of the lower extremity?
What is the current prophylaxis of venous thromboembolism in healthy long-distance travelers? What are the evidence-based recommendations?
In Poland, surgeons and internists often have different approaches to perioperative anticoagulation. What would be your advice for a physician who struggles to find a middle ground between the expectations of a surgeon and an internist?
Should a patient with a history of cerebral vein thrombosis travel by plane? What if the patient is currently not on anticoagulants?
Is it advisable to screen patients for the most common genetic thrombophilias before starting hormonal contraception?
Which hormonal contraceptives, routes of administration, and regimens are associated with the lowest risk of thrombosis?
Should female patients with a history of proximal thrombosis (affecting iliac vein or inferior vena cava) plan to become pregnant? What should be our recommendation for such patients? Does lack of recanalization of the affected vein pose additional problems?
What is new in the updated American College of Chest Physicians antithrombotic guidelines? What are the most important changes?
English
Polski
Español
українська